OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
, , , e | 17 dic 2015
INFORMAZIONI SU QUESTO ARTICOLO
Pubblicato online: 17 dic 2015
Pagine: 1 - 7
Ricevuto: 18 set 2015
Accettato: 30 set 2015
DOI: https://doi.org/10.1515/fco-2015-0014
Parole chiave
© 2015
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer